Albert Bourla, Pfizer CEO (Matthew Busch/Bloomberg via Getty Images)
March 10, 2023 10:33 AM EST
Pharma
FDA+
Marketing

Pfiz­er's mi­graine nasal spray from Bio­haven notch­es ap­proval

Beth Snyder Bulik

Senior Editor

Pfiz­er’s nabbed its first ap­proval out of its Bio­haven ac­qui­si­tion with a nod for mi­graine spray Za­vzpret on Fri­day. The FDA ap­proval al­so marks a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times